Doral, FL, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or, the “Company"), an innovative biotech company that operates in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device R&D, shares initial strategy and goals for 2018.

ETST had a successful 2017, filled with many important milestones. In continuing, the Company would like to share its goals and strategies for the first quarter of 2018 below with its shareholders.

In January, Earth Science Tech anticipates it will finalize its 2016 audit early on, which will then be utilized for the submission of the Tier II Regulation A+. The Company’s new SEC Counsel plans to have the Tier II Regulation A+ paperwork submitted within mid-January, once submitted and approved, ETST will file Form 8A with the SEC as part of the OTCQB up-listing process.

ETST plans to work closely with its non-profit, Earth Science Tech Foundation, to help children and adults suffering with cancer, epilepsy, depression, autism, chronic pain, and dementia. Based on numerous customers’ feedback, these mentioned conditions have been elevated and have demonstrated positive results with the Company’s CBD products. Key individuals and organizations are already in discussions to participate with the non-profit organization. The Company will also continue and expand its collaboration with a Canadian non-profit foundation under its agreement with Centre SIDA Amitié clinic. In January, ETST intends to announce a new collaboration with certain financial experts to attract major donors to partner with us and the Canadian non-profit foundation. The Company also expects that it will announce its collaboration with a start-up accelerator based in Montreal, which will serve to dramatically further branding objectives and dramatically increase the marketing of new nutraceutical products.

The Company expects to have its new, revamped CBD product line launched by the end of January, along with its new marketing material with its Mr. Checkout’s distribution network to further increase its brand presence and revenue.

In February, ETST plans to announce the addition of two new executives to its team. The new Chief Financial Officer (CFO) will help with the financials, auditing, and SEC reporting. The new Chief Sales Officer (CSO) comes from a big brand company with extensive experience which will help the Company to keep up with its growing sales team and demand for products. Gabriel Aviles, ETST’s current CSO, will transition to Chief Learning Officer (CLO) to help further educate Company representatives, store owners, and clients. Gabriel’s true passion is educating, and in his new position he will continue that role, but work with the new CSO to further increase product knowledge, trust, and sales.

ETST plans to take the final steps with its new Cannabidiol (CBD) formula to help fight the current opioid epidemic by initiating human clinical trials. Each of the medical professionals participating in this study and the new CBD formula look to be ready in February for the trials to begin.

Earth Science Tech is actively working on and intends to finish filing for a new trademark and graphic for its original medical device, MSN-2, in February. This is an important step that is necessary as part of the accreditation process with health authorities. Simultaneously, the Company hope to improve its Canadian manufacturing installation to become ISO-13485 certified. This certification is anticipated to help not only help bolster sales and allow the company to bring products to market more quickly.

The Company is hopeful that in March its Tier II Regulation A+ offering will have been approved by the SEC and be presented to institutions to commence funding. As mentioned in the end of 2017, funds will be utilized to complete Company projects for working capital and other expenses. In addition to filing the Form 1-A with the SEC, the Company also plans to file Form 8A and thereby commence regular continuing reporting with the SEC. Becoming a fully reporting company under the Securities Exchange Act of 1934, as amended, is an important step for the Company in its objective of up-listing, and the Company believes this additional transparency will make institutional investors more comfortable offering funding.

ETST also plans on expanding it’s team with a new Chief Operations Officer (COO) to keep the Company’s operations in order and efficient as it expands and progresses. Nickolas Tabraue will transition from his position as COO and continue on with the Company as its President and Director, concentrating on to implement the Company’s growth strategy and to further build the Company.

Michel Aubé PhD, Chief Science Officer states, “This is an incredible timing for our company. The Regulation A+ Tier II developed in 2015 is an amazing opportunity for us. Since we already build our credibility with high quality products and very well oriented R&D team. Because of the ability of our great management team on hiring key individuals sharing the same vision, passion, and acquiring scientific partners to achieve our mission we are in better position than ever before. From nothing, we build a network of collaborators that makes us competitive and we will clearly be recognized as a leader in cannabinoids research and other health science research arena. Our future is shining bright.”

ETST’s president, Director, & COO started the year by stating, “We look to hit the ground running in 2018 with all we have lined-up in the first quarter. Aside from the aforementioned items, we have other exciting discussions that are progressing well, and we will share those once any material developments have been finalized. Our story and vision will be seen very soon and we greatly appreciate all who have believed in us since the beginning.”

About Earth Science Tech, Inc. (ETST): Earth Science Tech has among the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the superior supercritical CO2 liquid extraction, our CBD Oil is 100% natural and organic. Our research, performed alongside the University of Central Oklahoma and DV Biologics laboratory, demonstrate that we are the top nutritional and dietary supplement brand for High Grade Hemp CBD Oil.

To learn more and to buy CBD Hemp Oil please visit:

About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.

To learn more please visit:

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide.

To learn more please visit:

About KannaBidioiD: KannaBidioid, Inc. is wholly owned subsidiary of Earth Science Tech, Inc. (ETST). KannaBidioid, Inc. is focused in the recreational space to manufacture and distribute vapes/e-liquids and gummy edibles in the recreational space formulated by its unique Kanna and CBD formula. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhance focus, and help with nicotine addiction based on their properties.

To learn more please visit:

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.


Contact Data